Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Cancer Oncology

Internal Medicine

Medicine

Cancer Oncology

Internal Medicine

Docetaxel

Androgen Deprivation Therapy

Show all topics

DOI

10.1016/s0140-6736(15)01037-5

License

CC-BY

Other Formats

PDF